Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Immunic

NASDAQ:IMUX

Stock Price:

$0.95 (-$0.03)

P/E Ratio:

-0.77

Market Cap:

$85.85 million

Average Trading Volume:

781,842 shares

Consensus Rating:

Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$12.67 (1,229.1% Upside)

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

#2 - Lucid Diagnostics

NASDAQ:LUCD

Stock Price:

$0.84 (-$0.00)

P/E Ratio:

-0.74

Market Cap:

$50.01 million

Average Trading Volume:

333,416 shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.63 (330.1% Upside)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

#3 - Unicycive Therapeutics

NASDAQ:UNCY

Stock Price:

$0.62 (+$0.01)

P/E Ratio:

-0.64

Market Cap:

$64.36 million

Average Trading Volume:

1.08 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.50 (787.1% Upside)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

#4 - Invivyd

NASDAQ:IVVD

Stock Price:

$0.41 (-$0.03)

P/E Ratio:

-0.21

Market Cap:

$48.61 million

Average Trading Volume:

1.01 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$7.89 (1,840.8% Upside)

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

#5 - Beyond Air

NASDAQ:XAIR

Stock Price:

$0.42 (+$0.04)

P/E Ratio:

-0.30

Market Cap:

$30.14 million

Average Trading Volume:

2.04 million shares

Consensus Rating:

Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.67 (778.2% Upside)

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

#6 - Elevation Oncology

NASDAQ:ELEV

Stock Price:

$0.71 (+$0.04)

P/E Ratio:

-0.87

Market Cap:

$42.05 million

Average Trading Volume:

1.47 million shares

Consensus Rating:

Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$7.20 (912.2% Upside)

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

#7 - Gossamer Bio

NASDAQ:GOSS

Stock Price:

$0.96 (-$0.04)

P/E Ratio:

-3.01

Market Cap:

$217.97 million

Average Trading Volume:

1.08 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.20 (856.4% Upside)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

#8 - Tempest Therapeutics

NASDAQ:TPST

Stock Price:

$0.93 (+$0.03)

P/E Ratio:

-0.61

Market Cap:

$40.40 million

Average Trading Volume:

1.84 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$20.00 (2,060.5% Upside)

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

#9 - Clearside Biomedical

NASDAQ:CLSD

Stock Price:

$0.93 (+$0.00)

P/E Ratio:

-2.07

Market Cap:

$70.52 million

Average Trading Volume:

303,411 shares

Consensus Rating:

Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.33 (473.5% Upside)

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

#10 - Century Therapeutics

NASDAQ:IPSC

Stock Price:

$0.91 (+$0.00)

P/E Ratio:

-0.49

Market Cap:

$77.32 million

Average Trading Volume:

547,848 shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$10.00 (999.7% Upside)

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

#11 - Lineage Cell Therapeutics

NYSEAMERICAN:LCTX

Stock Price:

$0.59 (+$0.02)

P/E Ratio:

-4.90

Market Cap:

$129.48 million

Average Trading Volume:

2.33 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.80 (717.2% Upside)

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

#12 - Mersana Therapeutics

NASDAQ:MRSN

Stock Price:

$0.62 (+$0.00)

P/E Ratio:

-1.01

Market Cap:

$76.42 million

Average Trading Volume:

1.55 million shares

Consensus Rating:

Moderate Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.57 (800.7% Upside)

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

#13 - Ovid Therapeutics

NASDAQ:OVID

Stock Price:

$0.74 (+$0.01)

P/E Ratio:

-1.57

Market Cap:

$52.55 million

Average Trading Volume:

253,735 shares

Consensus Rating:

Moderate Buy (5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.04 (445.9% Upside)

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

#14 - Nektar Therapeutics

NASDAQ:NKTR

Stock Price:

$0.89 (+$0.00)

P/E Ratio:

-1.06

Market Cap:

$164.54 million

Average Trading Volume:

1.33 million shares

Consensus Rating:

Moderate Buy (5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.08 (357.8% Upside)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

#15 - Cognition Therapeutics

NASDAQ:CGTX

Stock Price:

$0.68 (-$0.01)

P/E Ratio:

-0.70

Market Cap:

$28.33 million

Average Trading Volume:

18.75 million shares

Consensus Rating:

Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$8.30 (1,117.4% Upside)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

#16 - Omega Therapeutics

NASDAQ:OMGA

Stock Price:

$0.55 (-$0.02)

P/E Ratio:

-0.41

Market Cap:

$30.40 million

Average Trading Volume:

229,360 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.20 (1,575.8% Upside)

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

#17 - Oatly Group

NASDAQ:OTLY

Stock Price:

$0.69 (+$0.01)

P/E Ratio:

-1.00

Market Cap:

$411.78 million

Average Trading Volume:

2.75 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.27 (83.0% Upside)

Oatly Group AB, an oatmilk company, provides a range of plant-based dairy products made from oats in Europe, the Middle East, Africa, the Americas, and Asia. It offers Barista edition oatmilk, oatgurts, frozen desserts, ice-creams, and yogurts; cooking products, including cooking cream, in regular and organic, Crème Fraiche, whipping cream, vanilla custard, and spreads in a variety of flavors; and ready-to-go drinks. The company was formerly known as Havre Global AB and changed its name to Oatly Group AB in March 2021. Oatly Group AB was founded in 1994 and is headquartered in Malmö, Sweden.

#18 - Cresco Labs

OTCMKTS:CRLBF

Stock Price:

$0.89 (+$0.01)

P/E Ratio:

-4.45

Market Cap:

$434.45 million

Average Trading Volume:

890,694 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.50 (180.9% Upside)

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

#19 - Rallybio

NASDAQ:RLYB

Stock Price:

$0.88 (-$0.01)

P/E Ratio:

-0.55

Market Cap:

$36.31 million

Average Trading Volume:

94,663 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.75 (1,014.0% Upside)

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

#20 - Wag! Group

NASDAQ:PET

Stock Price:

$0.26 (-$0.00)

P/E Ratio:

-0.66

Market Cap:

$12.77 million

Average Trading Volume:

861,840 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.40 (1,615.4% Upside)

Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and pet insurance comparison tools. The company was founded in 2014 and is headquartered in San Francisco, California.

#21 - Viracta Therapeutics

NASDAQ:VIRX

Stock Price:

$0.17 (-$0.01)

P/E Ratio:

-0.15

Market Cap:

$6.71 million

Average Trading Volume:

2.18 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.05 (2,297.9% Upside)

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

#22 - Purple Innovation

NASDAQ:PRPL

Stock Price:

$0.95 (-$0.00)

P/E Ratio:

-0.95

Market Cap:

$102.16 million

Average Trading Volume:

363,278 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.53 (166.2% Upside)

Purple Innovation, Inc. designs and manufactures sleep and other products in the United States and internationally. The company offers mattresses, pillows, cushions, bases, sheets, platforms, adjustable bases, mattress protectors, foundations, blankets, duvets, duvet covers, seat cushions, and pet beds under the Purple brand. It markets and sells its products through its e-commerce online channels, retail brick-and-mortar wholesale partners, third-party online retailers, and Purple showrooms, as well as through its website, Purple.com. The company was founded in 2010 and is headquartered in Lehi, Utah.

#23 - Applied Therapeutics

NASDAQ:APLT

Stock Price:

$0.65 (+$0.03)

P/E Ratio:

-0.41

Market Cap:

$75.98 million

Average Trading Volume:

6.01 million shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$6.10 (834.2% Upside)

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

#24 - CytomX Therapeutics

NASDAQ:CTMX

Stock Price:

$0.84 (-$0.01)

P/E Ratio:

4.94

Market Cap:

$65.74 million

Average Trading Volume:

992,394 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.77 (587.2% Upside)

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

#25 - i-80 Gold

NYSE:IAUX

Stock Price:

$0.57 (-$0.04)

P/E Ratio:

-1.59

Market Cap:

$171.94 million

Average Trading Volume:

5.91 million shares

Consensus Rating:

Moderate Buy (1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.50 (511.9% Upside)

i-80 Gold Corp. is a mining company, engages in the exploration, development and production of gold and silver mineral deposits principally in the United States. i-80 Gold Corp. is based in Reno, Nevada.

More Stock Ideas from MarketBeat

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.